In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Antibiotics Deals are Blossoming

Executive Summary

Biotech has joined the new war on infectious diseases-for sound business reasons.

You may also be interested in...



Getting the Bugs Out of Antibiotic R&D: Commercial Implications of a Higher Regulatory Hurdle

It's a gloomy time for antibiotic R&D: higher regulatory hurdles and commercial challenges have forced many companies to leave the market. But a few major players and boutique firms remain committed to the field. What do they see that the rest of the industry is overlooking?

Roche Tries Again With Failed Huntington’s Drug Tominersen

Despite disappointment in its Phase III study, Roche is preparing a new trial of the antisense therapy in patients with a lower disease burden.

Evotec Adds To Spate Of Metabolic Deals With Eli Lilly Collaboration

The German biotech inks its fifth metabolic disease collaboration as it teams up with US major Eli Lilly to develop kidney disease and diabetes assets.

Topics

UsernamePublicRestriction

Register

IV000393

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel